Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $244M | $69M | $87M | $106M | 28.7% | 6775.0% | -146.4% |
| 2024 | $4M | $-208M | $-187M | $-163M | -32.8% | 2251.0% | 22.5% |
| 2023 | $0M | $-152M | $-153M | $-127M | -46.1% | - | 46.2% |
| 2022 | $0M | $-104M | $-105M | $-71M | -37.7% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0.15 | 3.55 | 244.06 |
| Operating Revenue | - | 0 | 0.15 | 3.55 | 244.06 |
| Operating Expense | - | 107.71 | 167.69 | 213.14 | 176.49 |
| Research And Development | - | 87.26 | 135.26 | 173.63 | 129.64 |
| Selling General And Administration | - | 27.52 | 34.83 | 40.75 | 46.85 |
| Total Expenses | - | 107.71 | 167.69 | 213.14 | 176.49 |
| Operating Income | - | -107.71 | -167.54 | -209.60 | 67.57 |
| Total Operating Income As Reported | - | -114.79 | -169.94 | -210.83 | 67.57 |
| EBITDA | - | -104 | -152.18 | -208.37 | 69.08 |
| Normalized EBITDA | - | -107.65 | -166.93 | -231.86 | 44.21 |
| EBIT | - | -104.68 | -152.99 | -209.60 | 67.57 |
| Interest Expense | 0 | 0 | 0 | 0 | - |
| Net Interest Income | 0 | 0 | 0 | 0 | - |
| Other Non Operating Income Expenses | - | -0.61 | -0.21 | -0.95 | -0.54 |
| Other Income Expense | - | 3.03 | 14.55 | 22.54 | 24.33 |
| Interest Expense Non Operating | 0 | 0 | 0 | 0 | - |
| Net Non Operating Interest Income Expense | 0 | 0 | 0 | 0 | - |
| Pretax Income | - | -104.68 | -152.99 | -187.05 | 91.90 |
| Tax Provision | - | 0 | 0 | 0.30 | 4.88 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 4.93 | 1.32 |
| Net Income Continuous Operations | - | -104.68 | -152.99 | -187.35 | 87.01 |
| Net Income From Continuing And Discontinued Operation | - | -104.68 | -152.99 | -187.35 | 87.01 |
| Net Income From Continuing Operation Net Minority Interest | - | -104.68 | -152.99 | -187.35 | 87.01 |
| Net Income | - | -104.68 | -152.99 | -187.35 | 87.01 |
| Net Income Common Stockholders | - | -104.68 | -152.99 | -187.35 | 87.01 |
| Net Income Including Noncontrolling Interests | - | -104.68 | -152.99 | -187.35 | 87.01 |
| Normalized Income | - | -108.32 | -167.75 | -205.91 | 63.46 |
| Diluted NI Availto Com Stockholders | - | -104.68 | -152.99 | -187.35 | 87.01 |
| Basic Average Shares | - | 23.44 | 29.45 | 37.44 | 37.22 |
| Diluted Average Shares | - | 23.44 | 29.45 | 37.44 | 37.86 |
| Reconciled Depreciation | - | 0.67 | 0.82 | 1.23 | 1.51 |
| Total Unusual Items | - | 3.64 | 14.76 | 23.50 | 24.87 |
| Total Unusual Items Excluding Goodwill | - | 3.64 | 14.76 | 23.50 | 24.87 |
| Gain On Sale Of Security | - | 3.64 | 14.76 | 23.50 | 24.87 |
| General And Administrative Expense | - | 27.52 | 34.83 | 40.75 | 46.85 |
| Other Gand A | - | 27.52 | 34.83 | 40.75 | 46.85 |
| Other Operating Expenses | - | -7.08 | -2.40 | -1.24 | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Keros Therapeutics, Inc.this co. | KROS | $213M | 2.45 | 0.70 | 28.7% | -0.83 |
| Foghorn Therapeutics Inc. | FHTX | $220M | -2.96 | -2.02 | 68.5% | -2.28 |
| Inhibikase Therapeutics, Inc. | IKT | $219M | -4.54 | 1.27 | -27.9% | -1.50 |
| Voyager Therapeutics, Inc. | VYGR | $219M | -1.83 | 1.12 | -61.1% | -1.49 |
| Utah Medical Products, Inc. | UTMD |
| - |
| - |
| - |
| - |
| - |
| $216M |
| 19.17 |
| 1.82 |
| 9.5% |
| 9.09 |
| Pro-Dex, Inc. | PDEX | $214M | 23.83 | 5.84 | 24.5% | 16.29 |
| RxSight, Inc. | RXST | $211M | -5.42 | 0.77 | -14.1% | -5.68 |
| Atrium Therapeutics, Inc. | RNA | $210M | -2.74 | 1.02 | -37.0% | 0.73 |
| Accendra Health, Inc. | ACH | $203M | -0.18 | -0.44 | 238.8% | 9.29 |
| Peer Median | - | -2.29 | 1.07 | -2.3% | -0.38 | |
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historically, Nov has averaged the highest return (+10.7%); Jun the lowest (-11.6%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -12.0%Negative MonthJan 2026: -12.03% | -20.8%Negative MonthFeb 2026: -20.77% | -22.2%Negative MonthMar 2026: -22.20% | +0.7%Neutral MonthApr 2026: +0.72% | +1.2%Neutral MonthMay 2026: +1.17% | -4.9%Negative MonthJun 2026: -4.89% | -5.9%Negative MonthJul 2026: -5.89% | +10.2%*Positive MonthAug 2026: +10.23% | — | — | — | — |
| 2025 | -28.0%Negative MonthJan 2025: -27.98% | -2.8%Negative MonthFeb 2025: -2.81% | -8.0%Negative MonthMar 2025: -8.03% | +41.7%Positive MonthApr 2025: +41.71% | -2.0%Negative MonthMay 2025: -2.01% | -5.7%Negative MonthJun 2025: -5.65% | +7.3%Positive MonthJul 2025: +7.27% | +6.2%Positive MonthAug 2025: +6.22% | +4.0%Positive MonthSep 2025: +4.01% | -3.8%Negative MonthOct 2025: -3.79% | +14.8%Positive MonthNov 2025: +14.85% | +16.5%Positive MonthDec 2025: +16.48% |
| 2024 | +39.2%Positive MonthJan 2024: +39.24% | +21.9%Positive MonthFeb 2024: +21.93% | -1.9%Neutral MonthMar 2024: -1.93% | -14.8%Negative MonthApr 2024: -14.82% | -16.9%Negative MonthMay 2024: -16.88% | -2.5%Negative MonthJun 2024: -2.50% | +9.8%Positive MonthJul 2024: +9.76% | -9.6%Negative MonthAug 2024: -9.59% | +28.0%Positive MonthSep 2024: +28.05% | -0.1%Neutral MonthOct 2024: -0.05% | -0.5%Neutral MonthNov 2024: -0.52% | -72.6%Negative MonthDec 2024: -72.58% |
| 2023 | +22.0%Positive MonthJan 2023: +21.97% | -9.1%Negative MonthFeb 2023: -9.13% | -19.8%Negative MonthMar 2023: -19.77% | +3.9%Positive MonthApr 2023: +3.88% | +7.9%Positive MonthMay 2023: +7.90% | -16.0%Negative MonthJun 2023: -16.05% | +4.2%Positive MonthJul 2023: +4.23% | -16.2%Negative MonthAug 2023: -16.17% | -9.2%Negative MonthSep 2023: -9.20% | -10.5%Negative MonthOct 2023: -10.48% | +6.3%Positive MonthNov 2023: +6.31% | +31.0%Positive MonthDec 2023: +31.05% |
| 2022 | -20.7%Negative MonthJan 2022: -20.75% | +15.8%Positive MonthFeb 2022: +15.81% | +1.3%Neutral MonthMar 2022: +1.27% | -2.5%Negative MonthApr 2022: -2.52% | -36.2%Negative MonthMay 2022: -36.24% | -18.3%Negative MonthJun 2022: -18.25% | +16.1%Positive MonthJul 2022: +16.11% | +10.3%Positive MonthAug 2022: +10.26% | +6.4%Positive MonthSep 2022: +6.36% | +33.8%Positive MonthOct 2022: +33.81% | -1.0%Neutral MonthNov 2022: -0.99% | -3.7%Negative MonthDec 2022: -3.65% |
| 2021 | — | — | — | — | -7.2%Negative MonthMay 2021: -7.21% | -22.2%Negative MonthJun 2021: -22.16% | -13.4%Negative MonthJul 2021: -13.35% | -8.6%Negative MonthAug 2021: -8.59% | +17.6%Positive MonthSep 2021: +17.60% | +5.5%Positive MonthOct 2021: +5.46% | +33.7%Positive MonthNov 2021: +33.72% | +4.9%Positive MonthDec 2021: +4.88% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
